10-K: Blue Water Acquisition Corp. III Files Annual Report

Blue Water Acquisition Corp. III, a blank check company, has filed its annual report for the year ended December 31, 2025, detailing its formation, initial public offering, and ongoing search for a business combination.

Summary

• Blue Water Acquisition Corp. III (BWAC III) is a blank check company incorporated in the Cayman Islands with no material operations as of December 31, 2025.
• The company's primary activities during the reporting period involved its formation, initial public offering (IPO), and the identification of potential business combination targets.
• BWAC III completed its IPO on June 11, 2025, raising $253 million by selling 25.3 million units.
• Simultaneously, it conducted a private placement, raising an additional $6.83 million.
• A significant event was the change of sponsor on November 25, 2025, with Yorkville BW Acquisition Sponsor, LLC becoming the new sponsor.
• The company has not yet identified a specific target business for its initial business combination and expects to focus on biotechnology, healthcare, and technology sectors.
• As of December 31, 2025, the company had a working capital deficiency of $109,004 and no operating revenues.
• The company's financial statements indicate substantial doubt about its ability to continue as a going concern.
• The company has two officers and no full-time employees prior to completing its initial business combination.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting the typical status of a SPAC that has completed its IPO and is in the process of searching for a business combination. While the IPO was successful, the lack of a target and the ongoing operational costs present standard SPAC risks.

Positives

• Successfully completed its Initial Public Offering (IPO) on June 11, 2025, raising $253 million.
• Successfully completed a private placement simultaneously with the IPO, raising an additional $6.83 million.
• Secured a new sponsor, Yorkville BW Acquisition Sponsor, LLC, on November 25, 2025, indicating continued support.
• The company's management team has significant experience in financial services and transaction execution.
• The company has a clear focus on identifying target businesses in biotechnology, healthcare, and technology sectors.

Negatives

• The company has no operating history and has not generated any revenues as of December 31, 2025.
• The company has a working capital deficiency of $109,004 as of December 31, 2025.
• The company's financial statements raise substantial doubt about its ability to continue as a going concern.
• The company has identified a material weakness in its internal control over financial reporting.
• The company faces significant competition from other SPACs and investment entities in identifying target businesses.
• There is a risk that the company may not be able to complete its initial business combination within the required timeframe, leading to liquidation.

Risks

• The company may not be able to identify and complete a suitable business combination within the 24-month completion window.
• A significant number of public shareholders may redeem their shares, reducing the capital available for a business combination.
• The company's ability to complete a business combination may be hindered by competition for attractive targets.
• Third-party claims against the company could reduce the funds available in the trust account.
• Changes in laws or regulations, or a failure to comply with them, could adversely affect the company's ability to complete a business combination.
• Global geopolitical conditions, outbreaks of infectious diseases, or other adverse global events could materially affect the search for and completion of a business combination.
• The company may be deemed an investment company under the Investment Company Act, which could lead to burdensome compliance requirements or hinder its ability to complete a business combination.
• The company's management team may have conflicts of interest in allocating their time and in selecting a target business.
• The company's structure and the potential for dilution from its securities may make it less attractive to potential target businesses.
• The company may be subject to U.S. federal excise tax on certain repurchases of stock if it domesticates as a U.S. corporation.

Future Outlook

The company is actively seeking a target business for its initial business combination, with a focus on biotechnology, healthcare, and technology sectors. The success of this endeavor is dependent on identifying a suitable target and completing the transaction within the specified timeframe, while managing potential shareholder redemptions and market conditions.

Management Comments

• The company's management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be generally applied toward consummating a Business Combination (less deferred underwriting commissions).
• The company's management believes that its structure and backgrounds will make it an attractive business partner to target businesses.
• Management is evaluating the impact of various macroeconomic factors and regulatory changes on the company's operations and search for a target.

Industry Context

StockSavvy.ai notes that Blue Water Acquisition Corp. III operates within the Special Purpose Acquisition Company (SPAC) sector, which has seen significant activity and regulatory scrutiny. The company's focus on biotechnology, healthcare, and technology aligns with current market trends for SPAC targets.

Comparison to Industry Standards

• The company's IPO structure, with units consisting of one Class A ordinary share and one-half of one redeemable warrant, is a common structure for SPACs.
• The company's stated intention to focus on specific sectors (biotechnology, healthcare, technology) is typical for SPACs seeking to leverage management expertise.
• The company's timeline for completing a business combination (24 months) is standard within the SPAC industry, with provisions for extensions.
• The company's reliance on a trust account for IPO proceeds is a standard practice for SPACs to ensure funds are available for the business combination or shareholder redemptions.

Management Changes

Legal Proceedings

• There is no material litigation, arbitration or governmental proceeding currently pending against the company or any members of its management team in their capacity as such.

Related Party Transactions

• The Prior Sponsor made capital contributions of $25,000 for 5,750,000 Founder Shares.
• The Company issued an additional 575,000 Founder Shares to the Prior Sponsor via share capitalization.
• The New Sponsor purchased 6,325,000 Founder Shares and 430,000 Private Placement Units from the Prior Sponsor for $7,200,000 on November 25, 2025.
• The Company entered into an administrative services agreement with the Prior Sponsor for office space, utilities, and administrative support at $10,000 per month, which was terminated on November 25, 2025.
• The Company incurred $54,398 in administrative costs paid to the Prior Sponsor.
• Kevin McGurn, CEO, receives a monthly advisory fee of $15,000, with $15,000 accrued and unpaid as of December 31, 2025.
• The Sponsor provided a promissory note for up to $300,000 for IPO expenses, which was repaid in full.
• The Sponsor issued a convertible unsecured promissory note for $500,000 on January 26, 2026, for working capital.

Stakeholder Impact

• Shareholders: The primary impact on shareholders is the ongoing search for a business combination. If successful, it could lead to value creation. If unsuccessful, shareholders may only receive their pro-rata portion of the trust account, and warrants could expire worthless.
• Sponsor: The Sponsor has invested capital and has a significant interest in the successful completion of a business combination to realize returns on its investment.
• Underwriters: Deferred underwriting fees of $8.855 million are contingent upon the completion of a business combination.

Next Steps

• Identify and evaluate potential target businesses for a business combination.
• Negotiate and structure a definitive agreement for a business combination.
• Obtain necessary shareholder approvals for the business combination.
• Complete the initial business combination within the specified timeframe.

Key Dates

Keywords

SPAC, Blank Check Company, Business Combination, IPO, Securities and Exchange Commission, Annual Report, Form 10-K, Cayman Islands, Yorkville, Biotechnology, Healthcare, Technology